Clearside Biomedical, Inc.
CLSD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,664 | $8,226 | $1,327 | $29,575 |
| % Growth | -79.8% | 519.9% | -95.5% | – |
| Cost of Goods Sold | $149 | $355 | $204 | $0 |
| Gross Profit | $1,515 | $7,871 | $1,123 | $29,575 |
| % Margin | 91% | 95.7% | 84.6% | 100% |
| R&D Expenses | $18,590 | $20,846 | $19,630 | $18,537 |
| G&A Expenses | $11,807 | $11,869 | $11,770 | $11,665 |
| SG&A Expenses | $11,807 | $11,869 | $11,770 | $11,665 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $30,397 | $32,715 | $31,400 | $30,202 |
| Operating Income | -$28,882 | -$24,844 | -$30,277 | -$627 |
| % Margin | -1,735.7% | -302% | -2,281.6% | -2.1% |
| Other Income/Exp. Net | -$5,470 | -$7,641 | -$2,670 | $1,003 |
| Pre-Tax Income | -$34,352 | -$32,485 | -$32,947 | $376 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$34,352 | -$32,485 | -$32,947 | $376 |
| % Margin | -2,064.4% | -394.9% | -2,482.8% | 1.3% |
| EPS | -7.05 | -7.95 | -8.25 | 0.096 |
| % Growth | 11.3% | 3.6% | -8,693.8% | – |
| EPS Diluted | -7.05 | -7.95 | -8.25 | 0.095 |
| Weighted Avg Shares Out | 4,920 | 4,120 | 4,014 | 3,899 |
| Weighted Avg Shares Out Dil | 4,920 | 4,120 | 4,014 | 3,994 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,462 | $1,719 | $669 | $0 |
| Interest Expense | $9,779 | $9,360 | $3,339 | $0 |
| Depreciation & Amortization | $226 | $67 | $145 | $178 |
| EBITDA | -$24,347 | -$23,058 | -$29,463 | $554 |
| % Margin | -1,463.2% | -280.3% | -2,220.3% | 1.9% |